行情

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.260
-0.050
-3.82%
盘后: 1.270 +0.01 +0.79% 19:53 01/21 EST
开盘
1.290
昨收
1.310
最高
1.300
最低
1.225
成交量
346.50万
成交额
--
52周最高
9.80
52周最低
1.225
市值
1.60亿
市盈率(TTM)
-1.4771
分时
5日
1月
3月
1年
5年
Atossa Therapeutics 宣布推进 AT-H201临床研究的 B 部分
Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE)
Benzinga · 4天前
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary DiseaseSEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a cli...
GlobeNewswire · 4天前
BRIEF-Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
reuters.com · 2021/12/22 14:36
Atossa Genetics Reports Begins Enrollment Of Phase 2 Study Of Oral Endoxifen In Sweden
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current
Benzinga · 2021/12/22 14:31
Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur
Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-C...
PR Newswire · 2021/12/16 14:00
BRIEF-Atossa Therapeutics Completes Pre-IND Meeting With U.S. Food & Drug Administration
reuters.com · 2021/12/06 14:18
Atossa Therapeutics Completes Pre-IND Meeting With FDA On Z-Endoxifen
 Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and
Benzinga · 2021/12/06 14:17
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 2021/12/05 11:38
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ATOS最新的财务预测,通过ATOS每股收益,每股净资产,每股现金流等数据分析Atossa Therapeutics Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ATOS价格均价为7.88,最高价位8.75,最低价为7.00。
最高8.75
均价7.88
最低7.00
现价1.260
EPS
实际EPS
预期EPS
-0.70-0.53-0.35-0.18
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 98
机构持股: 3,293.58万
持股比例: 26.01%
总股本: 1.27亿
类型机构数股数
增持
29
332.21万
建仓
20
287.05万
减持
25
742.73万
平仓
15
341.60万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
暂无数据
ATOS 简况
Atossa Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于发现和开发治疗乳腺癌和Covid-19的药物。该公司正在开发的Covid-19药物,包括AT-H201项目,适用于使用呼吸机的重症患者,而AT-301 COVID-19是一种鼻腔喷雾剂。该公司的鼻喷雾制剂AT-301旨在包含可能通过干扰宿主蛋白酶激活刺突蛋白、通过静电机制掩蔽受体结合域来阻断鼻上皮细胞中SARS-CoV-2病毒通过提供广泛的粘膜粘附上皮屏障进入基因蛋白。AT-H201计划是开发一种疗法来改善肺和功能,就像化学疫苗一样。该公司还正在开发Endoxifen的口服制剂,以降低乳房X光检查的乳房密度(MBD)并预防/减少开始雄激素剥夺治疗的前列腺癌患者的男性乳房发育症。

微牛提供Atossa Therapeutics Inc(NASDAQ-ATOS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATOS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATOS股票基本功能。